Q3 2025 Jazz Pharmaceuticals PLC Earnings Call Transcript
Key Points
- Jazz Pharmaceuticals PLC (JAZZ) achieved its highest-ever revenue quarter, surpassing $1.1 billion, driven by robust growth from Xywav, EPIDIOLEX, and the successful launch of Modeyso.
- The company secured two FDA approvals, including Modeyso for recurrent H3 K27M-mutant diffuse midline glioma and Zepzelca in combination with Atezolizumab for extensive-stage small cell lung cancer.
- Jazz Pharmaceuticals PLC (JAZZ) strengthened its early-stage epilepsy pipeline through a global licensing agreement with Saniona, acquiring worldwide rights to develop SAN2355.
- The company reported a 20% increase in EPIDIOLEX sales and an 11% increase in Xywav sales compared to the third quarter of 2024.
- Jazz Pharmaceuticals PLC (JAZZ) reached settlement agreements in the Xyrem Antitrust Litigation and litigation with Avadel, allowing the company to focus on executing its strategy.
- The potential entry of generic versions of high-sodium Xyrem in 2026 could disrupt Xywav revenue, depending on the number of generics entering the market and their pricing.
- Net product sales for Zepzelca decreased by 8% year over year due to competitive dynamics in the second-line setting.
- The overall asparaginase use has declined, impacting Rylaze sales, despite stable use within the asparaginase class for pediatric treatment.
- Jazz Pharmaceuticals PLC (JAZZ) faces uncertainties regarding the number and timing of generic entrants for Xyrem, which could affect market dynamics and revenue.
- The company anticipates potential payer actions that could disrupt Xywav revenue due to the availability of generics, requiring strategic partnerships with payers to maintain access.
Good day and thank you for standing by. Welcome to the Jazz Pharmaceuticals's 2025 third-quarter earnings conference call.
(Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Jack Spinks, Executive Director, Investor Relations. Please go ahead.
Thank you, operator. Good afternoon, everyone.
Today, Jazz Pharmaceuticals reported its third-quarter 2025 financial results. The slide presentation accompanying this podcast is available on the Investors section of our website.
Investors should also refer to the press release and the quarterly report on Form 10-Q that we issued earlier today. Both are available on our website and filed with the SEC.
On the call today are Renée Galá, President and Chief Executive Officer; Sam Pearce, Executive Vice President and Chief Commercial Officer; Robbie Iannone, Executive Vice President, Global Head
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
